Intravenous infusion of recombinant tissue plasminogen activator for the treatment of patients with sudden and/or chronic hearing loss

Annals of Otology, Rhinology and Laryngology

Volumn 112, Issue 8, 2003, Pages 665-670

  Mora, Renzo ^a   Barbieri, Marco ^a   Mora, Massimilliano ^a   Mora, Francesco ^a   Yoo, T J ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Chronic hearing loss; Sudden hearing loss; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEASIBILITY STUDY; HEARING; HUMAN; LINEAR REGRESSION ANALYSIS; LOW DRUG DOSE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SUDDEN DEAFNESS;

EID: 0042624939     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940311200802     Document Type: Article

References (34)

1. Schuknecht HE. Pathology of the ear. Cambridge, Mass: Harvard University Press, 1994:473-8.
2. Hughes GB, Pensak ML. Clinical otology. 2nd ed. New York, NY: Thieme, 1997:159-69, 294-5.
3. Hultcrantz E. Sudden deafness - a critical evaluation of pathogenesis and "cure." Otorhinolaryngol Nova 1999;9:178-89.
4. Wilson WR. The relationship of the herpesvirus family to sudden hearing loss: a prospective clinical study and literature review. Laryngoscope 1986;96:870-7.
5. Strauss M. A clinical pathologic study of hearing loss in congenital cytomegalovirus infection. Laryngoscope 1985;95:951-62.
6. Zechner G, Altmann F. The temporal bone in leukemia. Histological studies. Ann Otol Rhinol Laryngol 1969;78:375-87.
7. Kellerhals B, Hippert F, Pfaltz CR. Treatment of acute acoustic trauma with low molecular weight dextran. Pract Otorhinolaryngol 1954;59:731-8.
8. Veldman JE. Cochlear and retrocochlear immune-mediated inner ear disorders. Pathogenetic mechanisms and diagnostic tools. Ann Otol Rhinol Laryngol 1986;95:535-40.
9. Carey TE, Gray JP, Arts HA, et al. Antibody to inner ear supporting cells correlates with response to steroids in autoimmune loss [Abstract]. Inner Ear Biology Workshop, Helsinki, Finland, June 26-29, 1999:13.
10. Veldman J. Immune-mediated sensorineural hearing loss. Auris Nasus Larynx 1998;25:309-17.
11. Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J 1996;75:468-71, 474, 476.
12. Shiraishi T, Kubo T, Okumura S, et al. Hearing recovery in sudden deafness patients using a modified defibrinogenation therapy. Acta Otolaryngol Suppl (Stockh) 1993(suppl 501):46-50.
13. Rahko T, Kotti V. Comparison of carbogen inhalation and intravenous heparin infusion therapies in idiopathic sudden sensorineural hearing loss. Acta Otolaryngol Suppl (Stockh) 1997(suppl 529):86-7.
14. Walch C, Anderhuber W, Walzl M. H.E.L.P. therapy (heparin-induced extracorporeal LDL precipitation) in sudden deafness [in German]. Laryngorhinootologie 1996;75:641-5.
15. Kitamura K, Doi K, Takeda N, Mishiro Y, Okusa M, Kubo T. Statistical analysis of recovery from sudden deafness among treatment groups [in Japanese]. Nippon Jibiinkoka Gakkai Kaiho 1996;99:1676-83.
16. Weinaug P. Treatment of acute inner ear diseases (sudden deafness and vestibular disorder) with meclofenoxate and acetylsalicylic acid [in German]. HNO 1988;36:226-9.
17. Donaldson IA. Heparin therapy for sudden sensorineural hearing loss. Arch Otolaryngol 1979;105:351-4.
18. Wilson WR, Laird N, Moo-Young G, Soeldner JS, Kavesh DA, MacMeel JW. The relationship of idiopathic sudden hearing loss to diabetes mellitus. Laryngoscope 1982;92:155-60.
19. Goodhill V. Sudden deafness and round window rupture. Laryngoscope 1971;81:1462-74.
20. Simmons FB. The double-membrane break syndrome in sudden hearing loss. Laryngoscope 1979;89:59-66.
21. Gussen R. Sudden hearing loss associated with cochlear membrane rupture. Two human temporal bone reports. Arch Otolaryngol 1981;107:598-600.
22. Gussen R. Sudden deafness associated with bilateral Reissner's membrane ruptures. Am J Otolaryngol 1983;4:27-32.
23. Hagen R. Fibrinolytic therapy in sudden deafness with recombinant tissue-type plasminogen activator. Hemorheologic and therapeutic effects [in German]. Laryngorhinootologie 1991;70:353-8.
24. Banyai L, Varadi A, Patthy L. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator. FEBS Letts 1983;163:37-41.
25. Radcliffe R, Heinze T. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator? Arch Biochem Biophys 1981;211:750-61.
26. Lagares A, Gomez PA, Lobato RD, Alen IF, Campollo I, Benito-Leon J. Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction. Surg Neurol 1999;52:623-6.
27. Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II pilot and randomized clinical trial combined experience. Neurology 1995;45:649-58.
28. Sloan MA, Price TR, Terrin ML, et al. Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience. Stroke 1997;28:1107-14.
29. Yoo T, Nair U, Mora R, Kanangat S, Barbieri M. The recombinant tissue plasminogen activator (rTPA) up-regulates IL-8 and matrix metalloproteinase 1 [Abstract]. American Academy of Asthma, Allergy and Immunology, 2002.
30. Moll S, Menoud PA, Fulpius T, et al. Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. Kidney Int 1995;48:1459-68.
31. Kitching AR, Holdsworth SR, Ploplis VA, et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997:185:963-8.
32. Zhang LP, Takahara T, Yata Y, et al. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells. J Hepatol 1999;31:703-11.
33. Yoo TJ, Yazawa Y, Tomoda K, Floyd R. Type II collagen-induced autoimmune endolymphatic hydrops in guinea pig. Science 1983;222:65-7.
34. Galajda P, Martinka E, Kubisz P, Mokan M. Tkanivovy aktivator plazminogenu (tPA) a diabetes mellitus. Vnitr Lek 1998;44:661-4.